€240.8 1.8 0.8%
Last Trade - 11:35am
| Market Cap | ÂŁ8.80bn |
| Enterprise Value | ÂŁ7.41bn |
| Revenue | ÂŁ31.4m |
| Position in Universe | 82nd / 847 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.85 | 14.7 | 36.4 | 21.5 | 69.8 | 36.4 | 123.1 | 304.5 | +39.7% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | July 10, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 188 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | BEL 20 , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , |
| Exchange | Euronext - Brussels |
| Shares in Issue | 42,761,528 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Willemstraat 5, BREDA, 4811 AH, Netherlands |
| Web | |
| Phone | +31 76 3030488 |
| Contact | () |
| Auditors | Deloitte Accountants B.V. |
As of 11:35am, shares in argenx SE are trading at €240.8, giving the company a market capitalisation of £8.80bn. This share price information is delayed by 15 minutes.
Shares in argenx SE are currently trading at €240.8 and the price has moved by 74.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the argenx SE price has moved by 57.51% over the past year.
Of the analysts with advisory recommendations for argenx SE, there are there are currently 1 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for argenx SE is Hold. You can view the full broker recommendation list by unlocking its StockReport.
argenx SE is scheduled to issue upcoming financial results on the following dates:
argenx SE does not currently pay a dividend.
argenx SE does not currently pay a dividend.
argenx SE does not currently pay a dividend.
To buy shares in argenx SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in argenx SE are currently trading at €240.8, giving the company a market capitalisation of £8.80bn.
Here are the trading details for argenx SE:
Based on an overall assessment of its quality, value and momentum, argenx SE is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in argenx SE are currently priced at €240.8. At that level they are trading at 11.78% discount to the analyst consensus target price of 0.00.
Analysts covering argenx SE currently have a consensus Earnings Per Share (EPS) forecast of -12.708 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like argenx SE. Over the past six months, the relative strength of its shares against the market has been 17.26%. At the current price of €240.8, shares in argenx SE are trading at 5.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for argenx SE.
argenx SE's management team is headed by:
Here are the top five shareholders of argenx SE based on the size of their shareholding:
